PT - JOURNAL ARTICLE AU - Stoddard, Madison AU - Yuan, Lin AU - Sarkar, Sharanya AU - van Egeren, Debra AU - Mangalaganesh, Shruthi AU - Nolan, Ryan P. AU - Rogers, Michael S. AU - Hather, Greg AU - White, Laura F. AU - Chakravarty, Arijit TI - The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysis AID - 10.1101/2023.01.26.23285076 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.26.23285076 4099 - http://medrxiv.org/content/early/2023/01/29/2023.01.26.23285076.short 4100 - http://medrxiv.org/content/early/2023/01/29/2023.01.26.23285076.full AB - While the rapid deployment of SARS-CoV-2 vaccines had a significant impact on the ongoing COVID-19 pandemic, rapid viral immune evasion and waning neutralizing antibody titers have degraded vaccine efficacy. Nevertheless, vaccine manufacturers and public health authorities have a number of levers at their disposal to maximize the benefits of vaccination. Here, we use an agent-based modeling framework coupled with the outputs of a population pharmacokinetic model to examine the impact of boosting frequency and durability of vaccinal response on vaccine efficacy. Our work suggests that repeated dosing at frequent intervals (multiple times a year) may offset the degradation of vaccine efficacy, preserving their utility in managing the ongoing pandemic. Our work relies on assumptions about antibody accumulation and the tolerability of repeated vaccine doses. Given the practical significance of potential improvements in vaccinal utility, clinical research to better understand the effects of repeated vaccination would be highly impactful. These findings are particularly relevant as public health authorities worldwide seek to reduce the frequency of boosters to once a year or less. Our work suggests practical recommendations for vaccine manufacturers and public health authorities and draws attention to the possibility that better outcomes for SARS-CoV-2 public health remain within reach.Competing Interest StatementMS, LY, and AC are employees of Fractal Therapeutics, Inc. Fractal Therapeutics has no business interest in the topic of the article.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Re-implemented an agent based model from our prior work available at 10.1101/2022.08.30.22279397I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors